Literature DB >> 9593166

In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers.

P C Fuchs1, A L Barry, S D Brown.   

Abstract

Clinafloxacin was more active than ciprofloxacin against 4,213 aerobic and facultative anaerobic bacterial isolates from 10 medical centers, as tested by broth microdilution and disk diffusion methods. The percentage of 201 anaerobes susceptible to clinafloxacin by broth microdilution was comparable to cefoxitin. Our data support the proposed disk diffusion interpretive criteria for aerobic bacteria with 5-microg clinafloxacin disks.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9593166      PMCID： PMC105802          DOI： 10.1128/AAC.42.5.1274

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.

Authors:  P C Fuchs; A L Barry; M A Pfaller; S D Allen; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

2.  Pharmacokinetics and inflammatory fluid penetration of clinafloxacin.

Authors:  R Wise; S Jones; I Das; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

3.  Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates.

Authors:  R N Jones; D M Johnson
Journal:  Diagn Microbiol Infect Dis       Date:  1995-04       Impact factor: 2.803

4.  The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects.

Authors:  N J Bron; M B Dorr; T G Mant; C L Webb; A B Vassos
Journal:  J Antimicrob Chemother       Date:  1996-12       Impact factor: 5.790

5.  The comparative in vitro activity of clinafloxacin and other antimicrobials against vancomycin-susceptible and vancomycin-resistant enterococci.

Authors:  G S Itokazu; C Nathan; R Hariharan; J R Kostman; S A Kabins; R A Weinstein
Journal:  Chemotherapy       Date:  1996 Jul-Aug       Impact factor: 2.544

6.  In vitro susceptibility of anaerobes to quinolones in the United States.

Authors:  D W Hecht; H M Wexler
Journal:  Clin Infect Dis       Date:  1996-12       Impact factor: 9.079

7.  Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

8.  Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin.

Authors:  G D Harrington; L T Zarins; M A Ramsey; S F Bradley; C A Kauffman
Journal:  Diagn Microbiol Infect Dis       Date:  1995-01       Impact factor: 2.803

9.  Activities of three investigational fluoroquinolones (BAY y 3118, DU-6859a, and clinafloxacin) against Neisseria gonorrhoeae isolates with diminished susceptibilities to ciprofloxacin and ofloxacin.

Authors:  C J Carlyn; L J Doyle; C C Knapp; M D Ludwig; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

10.  In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; D Reeves; S M Finegold
Journal:  J Antimicrob Chemother       Date:  1994-10       Impact factor: 5.790
View more
  11 in total

1.  Activity of newer fluoroquinolones in vitro against gram-positive bacteria.

Authors:  G M Eliopoulos
Journal:  Drugs       Date:  1999       Impact factor: 9.546

2.  In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci.

Authors:  H J Linde; M Schmidt; E Fuchs; U Reischl; H H Niller; N Lehn
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 3.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Pharmacokinetics and pharmacodynamics of fluoroquinolones.

Authors:  J Turnidge
Journal:  Drugs       Date:  1999       Impact factor: 9.546

5.  Drug interactions with clinafloxacin.

Authors:  E J Randinitis; C W Alvey; J R Koup; G Rausch; R Abel; N J Bron; N J Hounslow; A B Vassos; A J Sedman
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

6.  Pharmacokinetics of clinafloxacin after single and multiple doses.

Authors:  E J Randinitis; J I Brodfuehrer; I Eiseman; A B Vassos
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

7.  Clinafloxacin pharmacokinetics in subjects with various degrees of renal function.

Authors:  E J Randinitis; J R Koup; G Rausch; R Abel; N J Bron; N J Hounslow; A B Vassos; A J Sedman
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

8.  Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections.

Authors:  J S Solomkin; S E Wilson; N V Christou; O D Rotstein; E P Dellinger; R S Bennion; R Pak; K Tack
Journal:  Ann Surg       Date:  2001-01       Impact factor: 12.969

9.  Comparative in vitro activities of clinafloxacin and trovafloxacin against 1,000 isolates of bacteroides fragilis group: effect of the medium on test results.

Authors:  D R Snydman; N V Jacobus; L A McDermott; S E Supran
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

10.  Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.

Authors:  M E Jones; M R Visser; M Klootwijk; P Heisig; J Verhoef; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.